AML SNV EvoSig #2 is also characterized by mutations of IDH1/2 genes, which are then followed by alterations in DNMT3A, rather than TET2, thus defining a group of patients with intermediate risk. This evidence concerns the gene IDH1 and acute myeloid leukemia.